| scholarly article | Q13442814 |
| P2093 | author name string | Yujin Kim | |
| Hong Kwan Kim | |||
| Young Mog Shim | |||
| Duk-Hwan Kim | |||
| Joungho Han | |||
| Bo Bin Lee | |||
| Dong Hao Jin | |||
| P2860 | cites work | Nuclear overexpression of the E2F3 transcription factor in human lung cancer. | Q53602672 |
| Activation and repression of p21(WAF1/CIP1) transcription by RB binding proteins | Q74465220 | ||
| E2F1 overexpression correlates with thymidylate synthase and survivin gene expressions and tumor proliferation in non small-cell lung cancer | Q80139021 | ||
| Characterization of E2F8, a novel E2F-like cell-cycle regulated repressor of E2F-activated transcription | Q24336562 | ||
| E2F7, a novel E2F featuring DP-independent repression of a subset of E2F-regulated genes | Q24633900 | ||
| Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources | Q27860739 | ||
| Combinational Therapy Enhances the Effects of Anti-IGF-1R mAb Figitumumab to Target Small Cell Lung Cancer | Q28547364 | ||
| p21 in cancer: intricate networks and multiple activities | Q30436015 | ||
| A20 modulates lipid metabolism and energy production to promote liver regeneration | Q33855522 | ||
| The E2F1-3 transcription factors are essential for cellular proliferation. | Q34102966 | ||
| Carnitine palmitoyltransferase 1A (CPT1A): a transcriptional target of PAX3-FKHR and mediates PAX3-FKHR-dependent motility in alveolar rhabdomyosarcoma cells | Q34245749 | ||
| Antiproliferative action of metformin in human lung cancer cell lines | Q34265863 | ||
| Emerging roles of E2Fs in cancer: an exit from cell cycle control | Q35009182 | ||
| Survival of patients with stage IV lung cancer with diabetes treated with metformin | Q35153493 | ||
| Metformin inhibits the proliferation of A549/CDDP cells by activating p38 mitogen-activated protein kinase | Q35224272 | ||
| E2F1 overexpression in quiescent fibroblasts leads to induction of cellular DNA synthesis and apoptosis. | Q35837977 | ||
| The E2F family: specific functions and overlapping interests | Q35945854 | ||
| E2F2 induction in related to cell proliferation and poor prognosis in non-small cell lung carcinoma | Q36261436 | ||
| E2F8 as a Novel Therapeutic Target for Lung Cancer | Q36294944 | ||
| Overexpression of MAPK15 in gastric cancer is associated with copy number gain and contributes to the stability of c-Jun | Q36299630 | ||
| Structural insights into the DNA-binding specificity of E2F family transcription factors | Q36392339 | ||
| Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK. | Q36896122 | ||
| E2f8 mediates tumor suppression in postnatal liver development | Q37137905 | ||
| Upregulation of E2F8 promotes cell proliferation and tumorigenicity in breast cancer by modulating G1/S phase transition. | Q37269121 | ||
| Atypical E2Fs: new players in the E2F transcription factor family | Q37388181 | ||
| Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein | Q37417220 | ||
| Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal | Q39014053 | ||
| The antidiabetic drug metformin inhibits the proliferation of bladder cancer cells in vitro and in vivo | Q39042097 | ||
| Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines. | Q39149019 | ||
| Dorsomorphin and LDN-193189 inhibit BMP-mediated Smad, p38 and Akt signalling in C2C12 cells. | Q39670303 | ||
| E2F8 contributes to human hepatocellular carcinoma via regulating cell proliferation. | Q39752834 | ||
| Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro | Q39883174 | ||
| The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. | Q40021818 | ||
| A role for E2F1 in Ras activation of p21(WAF1/CIP1) transcription | Q40895969 | ||
| Synergistic function of E2F7 and E2F8 is essential for cell survival and embryonic development. | Q43058346 | ||
| Metformin suppresses hepatocellular carcinoma cell growth through induction of cell cycle G1/G0 phase arrest and p21CIP and p27KIP expression and downregulation of cyclin D1 in vitro and in vivo. | Q51786739 | ||
| Mouse development and cell proliferation in the absence of D-cyclins. | Q52088064 | ||
| P433 | issue | 60 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | metformin | Q19484 |
| P304 | page(s) | 101509-101519 | |
| P577 | publication date | 2017-10-06 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Metformin induces cell cycle arrest at the G1 phase through E2F8 suppression in lung cancer cells | |
| P478 | volume | 8 |
| Q92989938 | Carcinogenesis effects of E2F transcription factor 8 (E2F8) in hepatocellular carcinoma outcomes: an integrated bioinformatic report |
| Q59803813 | E2F transcription factor 8 promotes cell proliferation via CCND1/p21 in esophageal squamous cell carcinoma |
| Q61807404 | Metformin Inhibit Lung Cancer Cell Growth and Invasion in Vitro as Well as Tumor Formation in Vivo Partially by Activating PP2A |
| Q55153270 | Transcriptional E2F1/2/5/8 as potential targets and transcriptional E2F3/6/7 as new biomarkers for the prognosis of human lung carcinoma. |
Search more.